deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02746991

Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis

A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye

Sponsor: EyePoint Pharmaceuticals, Inc.

Updated 14 times since 2017 Last updated: Jul 10, 2020 Started: Jun 2, 2015 Primary completion: Oct 4, 2019 Completion: Oct 4, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02746991, this PHASE3 trial focuses on Intermediate Uveitis and Panuveitis and remains completed. Sponsored by EyePoint Pharmaceuticals, Inc., it has been updated 14 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~May 2020 · 23 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Dec 2022 · 14 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

Show 9 earlier versions
  1. Oct 2021 — Dec 2022 [monthly]

    Completed PHASE3

  2. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE3

  3. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Unknown StatusCompleted

  4. Jul 2020 — Aug 2020 [monthly]

    Unknown Status PHASE3

    Status: Active Not RecruitingUnknown Status

  5. May 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Aug 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • EyePoint Pharmaceuticals, Inc.
Data source: EyePoint Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .